WHI Study Pages

Note: This landing page is still being maintained, but may eventually be phased out. To search for and learn about our Ancillary Studies, please consider visiting the "Studies" page on the new WHI website.

The pages hosted on this site provide detailed information about each WHI study. Detailed information on each page can include:

Study summary including introduction, results or publications, discussions, and references
Case/control/cohort sample selection and/or recruitment documents
Other relevant study documents
Data Dictionaries and data preparation documents
Study data, including raw and analytical datasets.

Note that biospecimens results are not included on these pages, and are instead included under Specimen Results under the Data tab.

In addition, Guidelines for AS Biospecimen Data Submission are available to ancillary study and BAA investigators on how to submit their study data to WHI. Beginning in 2013, study PIs are responsible for updating their specific study page with both the study information and study data. See the guidelines and Help Topics for further information.

Access to the detailed information on each Study page is open to the public. Access to study data has the same requirements as access to other WHI data, in which the investigator must sign a WHI Data Use Agreementand submit it to the WHI Helpdesk.

ID	Study Name	PI Name	CASE CONTROLS
AS5	Explanations for the development of fat distaste	Pamela Green	DM
AS9	Oral bone loss	Marjorie Jeffcoat	OS 450 Ppts @ Birmingham
AS11	Validation and exploration of sleep and mood predictors	Daniel Kripke	OS
AS13	Prevalence and correlates of lumbar spinal stenosis	Molly Vogt	CT
AS14	High density lipoprotein metabolism	Scott Going	OS
AS15	The relationship between osteopenia and periodontitis	Jean Wactawski-Wende	OS
AS17	Domestic violence in older women	Charles Mouton	OS
AS24	Cross-ethnic comparisons of skeletal health of postmenopausal women in San Diego county	Diane Schneider	OS
AS25	Ankle-arm blood pressure index measurement	Kamal Masaki	OS
AS31	Eye care use	Robert Kleinstein	OS
AS33	The association of HRT with abdominal and total body fat in postmenopausal women	Charlotte Mayo	OS
AS34	Ethnic differences in hip bone geometry by DXA and QCT	Dorothy Nelson	HT
AS36	HRT and changes in mammographic density	Barbara Hulka	HT breast C. (,0)
AS39	The effects of HRT on the development and progression of dementia (WHIMS)	Sally Shumaker	HT
AS40	Ethnic and age differences in use of mammography	Sylvia Smoller	OS
AS47	Effect of diet intervention on motivation to make other health-related changes	Robert Langer	DM
AS48	Prostate cancer survey of spouses of WHI screened women	Sylvia Smoller	General population
AS50	Nutrition practice guidelines for maintaining low-fat dietary change in post menopausal women	Beth Burrows	DM
AS56	Behavioral and psychosocial predictors of dietary change in postmenopausal women	Joan Pleuss	DM
AS57	Hispanic women's advocacy and retention strategies	Cheryl Ritenbaugh	OS
AS60	Fat intake in husbands of WHI dietary arm participants	James Shikany	DM
AS61	Longitudinal assessment of memory functioning in the WHI clinical trial	Beth Ober	HT
AS62	Prevention of age-related maculopathy in the WHI HRT CT: WHI-SE	Mary Haan	HT
AS63	Development and evaluation of eating style index	Pam Haines	OS
AS65	Benign breast disease	Tom Rohan	DM
AS68	Coronary artery calcification detected with ultrafast CT as an indication of CAD in OS participants	Judith Hsia	OS
AS70	The prevalence and prognostic importance of myocardial ischemia during daily life, and its relationship to migraine status: WHI	David Sheps	OS
AS73	Psychosocial and cultural determinants of NIDDM in Latinas	Cheryl Ritenbaugh	OS
AS74	The effectiveness of individual versus group behavioral strategies to increase participants adherence	Lois Wodarski	DM
AS75	Adherence to dietary modification in the WHI	Milagros Rosal	DM
AS76	Tailored messages to enhance adherence of older women to dietary programs for breast cancer control	Rowan Chlebowski	DM
AS78	Community strategy to retain women enrolled in research	Mona Fouad	CT
AS82	Extension of bone mineral density assessment in WHI Native American women	Zhao Chen	OS
AS83	Thrombotic, inflammatory and genetic markers for coronary heart disease in postmenopausal women: a WHI umbrella study	Paul Ridker	OS chd (650,0) Controls (650)
AS84	Cognitive change in women	Julie Dunn	General population
AS86	A pilot study to determine the sensitivity of form 39 to impaired executive controlfunction (ECF) as measured by the CLOX: an executive clock-drawing task	M.J. Polk	HT
AS90	WHI sex hormone and genetic risk factors for hip fracture	Steve Cummings	OS fracture - hip (400,400) Controls (400) same as AS181
AS93	The epidemiology of venous disease	Michael Criqui	OS
AS95	Work organization, psychological distress, and health among minority older women	Beatriz Rodriguez	OS
AS97	Modeling serum markers for cost-effective ovarian cancer screening	Garnet Anderson	OS ovarian C. (280,280) Controls (558)
AS98	Bone mineral density as a predictor for periodontitis	Jean Wactawski-Wende	OS
AS99	Genetics of non-insulin dependent diabetes (GENNID)	Rowan Chlebowski	General population
AS100	Genetic, biochemical and behavioral determinants of obesity	Jennifer Hays	OS
AS102	Quality of life improvements and willingness to pay: an investigation of selective estrogen receptor modulators	Mona Fouad	OS
AS103	Effects of hormone replacement therapy on cognitive aging: Women's Health Initiative study of cognitive aging (WHISCA)	Sally Shumaker	HT 2266 ppts at 15 clinics
AS104	Tamoxifen prevention: Is it acceptable to women at risk?	Joy Melnikow	OS
AS105	Carotenoids in age-related eye disease study (also see M1)	Julie Mares	OS eye (1000,2004) Controls (1000)
AS108	Gene-environment effects and colorectal cancer	Henry Lin	OS colorectal C. (50,50) Controls (150)
AS110	Sex steroid hormones and risk of coronary heart disease: a nested case control study	Kathryn Rexrode	OS chd (385,695) Controls (385) 79 matched cases-controls and 92 cases (but not controls) overlap with AS83.
AS111	Glycemic index/glycemic load and blood lipids in the WHI	James Shikany	General population
AS113	Some aspects of mediterranean diet in relation to risk of chronic diseases among postmenopausal women	Iman Hakim	OS
AS117	Risk factors for dry eye syndrome in postmenopausal women	Kelley Nichols	OS
AS118	Accuracy of food portion estimation among postmenopausal women	Christine Coy	DM
AS121	Hyperinsulinemia and ovarian cancer	Francesmary Modugno	OS ovarian C. (225,225) Controls (225) originally a subset of AS97
AS122	Feasibility study of computerized tailored dietary feedback	Karen Glanz	DM
AS124	Sociocultural influences on motivation for and maintenance of health-related dietary change among women	Joylin Namie	DM
AS126	Stroke risk factors and molecular markers in postmenopausal women	Sylvia Wassertheil-Smoller	OS stroke (972,972) Controls (972)
AS127	CHD risk perception study	Janice Barnhart	OS
AS129	Association of diabetes and insulin-like growth factor-I (IGF-I) with risks of colorectal, breast, and endometrial cancer	Howard Strickler	OS endometrial C. (300,300) colorectal C. (500,500) breast C. (900,900) Controls (900) same as AS152
AS130	Randomized controlled trial of fat reduction, calcium/Vitamin D supplementation, hormone replacement therapy, and risk of proliferative forms of benign breast disease	Tom Rohan	CT benign breast disease (,3901) Controls (0)
AS132	A prospective study of genetic and biochemical predictors of type 2 diabetes mellitus	Simin Liu	OS type 2 diabetes (1800,1800) Controls (2500)
AS133	Biochemical and genetic predictors of incident hypertension in white and black women	Howard Sesso	OS hypertension (800,0) Controls (800)
AS134	Serum estrogen hormone metabolites, hormone replacement therapy and the risk of breast cancer	Francesmary Modugno	OS breast C. (200,200) Controls (200)
AS135	Natural history of pelvic organ prolapse in WHI women	Ingrid Nygaard	HT
AS137	Postmenopause CHD risk: platelet genes and hormone therapy	Paul Bray	OS chd (1060,1060) Controls (2120)
AS139	Follow-up of healthy breast cancer survivors in the WHI observational study	Electra Paskett	OS
AS140	Air pollution and electrocardiographic abnormalities (environmental epidemiology of arrhythmogenesis in WHI)	Eric Whitsel	CT
AS141	Periodontal disease and subclinical cardiovascular disease in post-menopausal women	Joan Dorn	OS
AS146	A prospective study of pancreatic cancer pathogenesis	Charles Fuchs	OS pancreatic C. (104,104) Controls (312)
AS150	Effect of airborne particulate matter and other air pollutants on the incidence of cardiovascular events in the Women's Health Initiative observational study	Joel Kaufman	General population chd (,0)
AS152	Growth factor genes and female breast, colorectal, and endometrial cancers	Gloria Ho	OS colorectal C. (500,500) endometrial C. (300,300) breast C. (900,900) Controls (900) Same as AS129
AS153	Longitudinal changes in hip geometry and skeletal muscle	Zhao Chen	OS fracture - hip (,0)
AS160	An assessment of symptoms and symptom self-management for women abruptly stopping hormone replacement study pills	Barbara Valanis	HT E+P
AS161	Bone mass response to termination of estrogen + progestin	Jane Cauley	HT E+P
AS163	Hormone use following the WHI E+P trial termination: a pilot study	Jennifer Hays	HT E+P
AS165	Subclinical thyroid dysfunction and risk of myocardial infarction and stroke	Carol Lorenz	OS stroke (591,591) chd (800,800) Controls (3136)
AS167	Sex hormones, risk factors, and risk of ER+ and ER- breast cancer	Steve Cummings	OS breast C. (311,0) Controls (592)
AS171	Analysis of heart rate variability from ultra-short records: the WHI study	Yvonne Michael	CT
AS175	Physical function determinants in minority women	J. Skye Nicholas	OS
AS177	Relative risk differences between FFQs and food records	Amy Subar	DM
AS178	Mammographic density and invasive breast cancer	Etta Pisano	CT breast C. (,0)
AS179	Frailty in WHI: drugs, inflammatory and genetic markers	Andrea LaCroix	OS frailty-disability (900,0) Controls (900)
AS181	Estradiol, cytokines, and bone turnover: effects on hip fracture	Jane Cauley	OS fracture - hip (400,400) Controls (400) same as AS90
AS183	Effects of hormone therapy on subclinical neurological pathology: WHIMS-MRI	Sally Shumaker	HT E+P 1450 ppts at 14 WHIMS clinics
AS187	Serum fatty acids and incidence of ischemic stroke in women	Ka He	OS stroke (971,972) Controls (971) shares cases and controls with AS 126
AS189	Biochemical and anthropometric heterogeneity among morbid obese women in the Women's Health Initiative observational study	Rachel Mackey	OS chd (144,0) Controls (1172)
AS191	Biomarkers and genetic factors related to sarcopenia in older women (includes AS199)	Zhao Chen	OS sarcopenia (2800,0) 2800 for DNA, subset of 1400 for EDTA
AS192	Estrogen and progesterone-related genes and colorectal cancer risk	Shumin Zhang	OS colorectal C. (644,0) Controls (1288) Requests 10% blind duplicates (96 pairs)
AS195	Candidate pathways in colorectal carcinogenesis: one-carbon metabolism and inflammation	Cornelia Ulrich	OS colorectal C. (988,0) Controls (988) Same cases/controls as AS 206 where possible
AS196	Heart failure evaluation in post-menopausal women: the Women's Health Initiative study	Liviu Klein	HT
AS197	Validity of self-reported diabetes mellitus in the Women's Health Initiative	Karen Margolis	CT
AS199	Genetic factors of muscle loss (added to AS191)	Zhao Chen	OS sarcopenia (800,0) Controls (2000) Combined with AS191
AS206	The effects of estrogen-alone hormone therapy on body composition	Ulrike Peters	OS colorectal C. (805,0) Controls (805) Same cases/controls as AS195; controls include 100 Y3 samples
AS207	IGF and multiple myeloma	Graham Colditz	General population multiple myeloma (197,0) Controls (394)
AS208	Pro and anti-inflammatory cytokines and colorectal cancer	Gloria Ho	OS colorectal C. (500,500) Controls (900) same cases/controls as AS 129
AS214	Prospective cohort collaborative in pancreatic cancer epidemiology and pathogenesis (AS146 extension)	Charles Fuchs	OS pancreatic C. (209,0) Controls (418) Assays done on those missing in AS146; Pilot: 40 AV3 samples from controls
AS216	Decision-making about cancer screening among older women	Catherine Messina	General population 1300 Ppts @ Stonybrook
AS217	Validation of the self-report of rheumatoid arthritis and systemic lupus erythematosus: The Women's Health Initiative	Brian Walitt	CT
AS218	WHI nutrition and physical activity assessment study (NPAAS)	Ross Prentice	OS 450 Ppts @ 9 clinics 450 Ppts @ 9 clinics
AS219	Diet and eye health in the WHI: end of trial study: pilot study	Julie Mares	DM
AS220	Neighborhoods, women, and coronary heart disease: a prospective study	Cloe Bird	General population
AS223	Women's Health Initiative cancer survivor cohort: biological, psychosocial, and behavioral predictors of survival: pilot study	Electra Paskett	General population
AS224	GWAS for nonsynonymous SNPs in colon cancer	Ulrike Peters	General population colon C. (1309,2063) Controls (1309) Stage 1: GWAS 556 cases/69 controls, Caucasian only; Stage 2: GWAS 1309/1309 cases/controls; Stage 3: 7600 SNPs
AS226	Socioeconomic and environmental disparity of sleep disturbance	Jiu-Chiuan Chen	General population
AS233	WHIMS (AS39) extension	Sally Shumaker	HT 3070 Ppts @ 32 clinics
AS235	Pilot study to explore assoc between task performance on fMRI w/ cog functioning and vascular, genetic & inflam. risk factors in WHISCA ppt characterized by differing body weight & waist-hip ratios	Diana Kerwin	CT 122 Ppts @ Milwaukie
AS236	Choline/betaine habitual intake and chronic disease endpoints	Anna Maria Siega-Riz	General population
AS238	Biochemical predictors of type 2 DM in women	Simin Liu	OS type 2 diabetes (700,699) Controls (1400) Only minorities from AS132
AS242	DNA repair, telomere length and cutaneous malignant melanoma risk	Jiali Han	OS melanoma - skin (259,0) Controls (259) Malignant melanoma
AS243	Validation of direct measures of physical activity: an ancillary study to the Women's Health Initiative (WHI) Nutrition and Physical Activity Assessment Study (NPAAS; AS218)	Barbara Sternfeld	OS 70 Ppts @ Oakland
AS244	Women's Health Initiative memory study epidemiology of cognitive health (WHIMS-ECHO)	Sally Shumaker	HT
AS250	Genetic contributions to cognitive decline in normal and pathological aging in older post-menopausal women and modification by hormone therapy	Ira Driscoll	HT Controls (7479) Phase 1: 2,266 WHISCA; Phase 2: 719 WHIMS. Phase 3 not yet funded for remaining 4,500 WHIMS
AS251	Acute cardiovascular disease & air pollution in WHI-Phase I	Greg Wellenius	General population
AS252	Environmental determinants of cognitive aging in WHIMS	Jiu-Chiuan Chen	HT HRT E+P in WHIMS (4532) HRT E-alone in WHIMS (2947) WHIMS-Y (2800)
AS254	Telomere and its biochemical and genetic regulators as predictors for clinical diabetes in women	Simin Liu	OS type 2 diabetes (1800,0) Controls (2620)
AS257	Nutritional and genetic risk factors for age-related macular degeneration	Julie Mares	OS eye (361,0) Controls (1426) PI has a list of participants from AS105-CAREDS
AS262	Women's Health Initiative memory study of younger women (WHIMS-Y)	Sally Shumaker	HT All HT ppts aged 50-54 at randomization
AS263	Gene-hormone therapy interaction and the risk of breast cancer	Jielin Sun	General population breast C. - invasive (2690,0) Controls (1800) 583 E+P and 307 E-alone cases for GWAS; 1800 OS case/control pairs for sequencing
AS264	Modification of PM-Mediated Arrhythmogenesis in Populations (MOPMAP)	Eric Whitsel	General population Controls (3094) 5 geographical locations; ppts with ECG readings
AS266	Serum levels of EGFR-signaling-network activators/inhibitor and risk of lung cancer	Gloria Ho	General population C. of lung (1384,0) Controls (1601) 1:2 matching for never smokers, 1:1 matching for former/current smokers; 321 CT control ppts; 500 cases from BA06
AS271	Omega-3 and omega-6 fatty acids as a biomarker of hip fracture risk	Rebecca Jackson	General population fracture - hip (400,0) Controls (400) half BMD, half non-BMD
AS272	WHI Nutrition and Physical Activity Assessment Study (NPAAS) (Competitive Renewal)	Ross Prentice	General population
AS275	Urinary levels of melatonin and risk of breast cancer	Susan Sturgeon	OS breast C. - invasive (260,0) Controls (519)
AS282	Evaluation of serum markers for use in multi-stage ovarian cancer screening	Nicole Urban	General population ovarian C. (183,463) Controls (732)
AS284	Obesity-related pathways and risk of benign proliferative breast disease	Tom Rohan	CT benign breast disease (700,0) Controls (1400)
AS286	OPACH: Objective physical activity and cardiovascular health in women aged 80 and older	Andrea LaCroix	General population 6500 E+P women, 2500 E - alone women, 1000 SHARe participants
AS287	Metabolic Syndrome, Lifestyle Factors and Risk of Periodontitis in Older Women	Michael LaMonte	CT,OS completed comprehensive dental exam at baseline and 5 years (670)
AS289	Pooling validation studies with recovery biomarkers	Victor Kipnis	DM NBS sub-study (544)
AS290	Cadmium exposure and risk of breast cancer in the WHI	Polly Newcomb	General population breast C. - invasive (508,0) Controls (1000)
AS292	Advanced glycation end products, the receptor, and colorectal cancer risk in WHI	Li Jiao	OS colorectal C. (425,0) Controls (791) From AS129
AS294	Investigation of one-carbon metabolism pathway and lung cancer with the cohort consortium	Paul Brennan	General population C. of lung (238,242) Controls (238)
AS296	Cohort consortium study of etiology of hepatocellular carcinoma in the United States	Katherine McGlynn	General population C. of liver (121,0) Controls (242)
AS297	Associations of estrogens, estrogen metabolites, and androgens with risks of endometrial and ovarian cancers in a prospective case-cohort study	Britton Trabert	OS endometrial C. (430,0) ovarian C. (240,0) Controls (540)
AS301	GWAS of Non-Hodgkins Lymphoma	Sonja Berndt	General population Lymphoma, non hodgkins (1,580) Multiple myeloma (349) Hodgkin lymphoma (47) Controls (700)
AS303	Saliva and serum inflammatory biomarkers in periodontitis: A study in older women	Jean Wactawski-Wende	General population
AS304	Vitamin D status and periodontal disease	Amy Millen	General population
AS308	Heavy metals and renal cell cancer risk (Pilot study)	Robin Wilson	General population
AS311	Global DNA methylation measured in prospectively collected blood samples and risk of bladder cancer among post-menopausal women	Parveen Bhatti	General population C. of bladder (530,0) Controls (530) Specifically papillary transitional cell bladder cancer
AS315	Epigenetic Mechanisms of PM-Mediated CVD Risk	Eric Whitsel	CT Controls (4167) 4,167 ppts from 6% CT subsample
AS316	Validation of promising breast cancer early detection biomarkers	Christopher Li	OS breast C. - invasive (322,0) Controls (322) blood within 17 months of dx; exclude cases from BA05
AS321	Gentoxic Estrogen Ratio: A Novel Estrogen Biomarker and Breast Cancer Risk	Kerryn Reding	OS, DM Breast C.- invasive (481) Controls (481)
AS325	Racial/Ethnic Differences in 25(OH)D and PTH Levels and CVD among Women	Yiqing Song	OS White CVD cases (1,500) White non-cases (1,500) Black CVD cases (550) Black non-cases (1,300)
AS327	Serum 25-hydroxyvitamin D and lung cancer risk in never-smoking, postmenopausal women	Marian Neuhouser	General population C. of lung (300,0) Controls (300)
AS332	Utility of the AVIIR score in predicting incident coronary heart disease in the WHI	Themistocles (Tim) Assimes	General population chd (700,0) Controls (700) case cohort design ~700 cases with incident CHD within 5 years of baseline/700 random controls
AS337	Lymphocyte subpopulations and clonal expansions in older women: epidemiologic factors and relationship to health and aging during the WHI 2010-2015 Extension	Kerstin Edlefsen	CT first 2,000 women (50% white, 50% African American) from the Home Visit
AS340	Evidence for Establishing Optimum Protein Intake in Older Adults	Jeannette Beasley	General population
AS343	Cardiovascular disease biomarkers and mediation of hormone therapy effects	Ross Prentice	HT chd (20,20) stroke (22,20) Controls (42) Cases and controls are from the W57 participants in the 6% subsample
AS346	Serum, vitamin D, and risk of melanoma in WHI-OS	Jean Tang	OS melanoma - skin (718,0) Controls (718) Whites only
AS349	Exomic analysis of cardiovascular risk factors in minority women from WHI	Charles Kooperberg	OS, CT dbGaP-eligible (20,000) ~12,151 African American ~5,468 Hispanic ~3,500 Asian ~600 Native American ~6,000 European American
AS352	(Pilot study) Trial of a cocoa supplement and multivitamin for CVD and cancer prevention among WHI participants	JoAnn Manson	General population
AS355	Trial of a cocoa supplement and multivitamin for CVD and cancer prevention among WHI participants	JoAnn Manson	OS, CT High risk of CVD (12,000)
AS362	Advanced Glycation End-products and Risk of Obesity-related Pancreatic Cancer		OS, CT There is overlap between the two aims: Serological Aim: 1,480 (494 pancreatic cancer cases + 986 controls) Genetic Aim: 2,144 (715 pancreatic cancer cases + 1,429 controls)
AS370	WHI cancer survivor cohort (LILAC)	Garnet Anderson	General population
AS373	Understanding older smokers' unique challenges in quitting: prelude to a smoking cessation RCT in the WHI extension 2	Hilary Tindle	General population OS smokers at year 6 or close-out (400; SE RC ppts only) CT smokers at year 6 or close-out (400; SE RC ppts only)
AS374	Biomarkers of HPV infection and risk of two increasing cancers within the NCI cohort consortium	Paul Brennan Nicolas Schlecht	OS, CT Head/neck cancer (61) Anal cancer (85) Vaginal cancer (29) Controls (350)
AS376	Estrogen therapy and incident end-stage renal disease in post-menopausal women	Nora Franceschini	General population
AS377	Health risks and benefits from calcium and vitamin D supplementations: analysis of WHI data	Ross Prentice	General population
AS383	Circulating vitamin D levels & risk of breast and colorectal cancer: a pooled analysis	Stephanie Smith-Warner	CaD breast C. - noninvasive (29,0) colorectal C. (29,0) From W24 and W15
AS384	Methylation profiling of early stage lung tumors in short and long-term survivors (Pilot to AS370)	Garnet Anderson	General population
AS386	Natural environment and cardiovascular incidence and mortality: The WHI	Geoffrey Donovan	General population
AS389	A Pooled Investigation of Multiple Myeloma Risk in Relation to Circulating Adiponectin Levels
AS391	Defining and timing of sudden arrhythmic death in WHI	Charles Eaton	General population
AS397	Assessment of fibromyalgia and polysomatic distress in the Women’s Health Initiative: Pilot study	Brian Wallit	OS, CT (593)
AS398	Enhanced dietary assessment to evaluate post-trial cancer outcomes in the WHI Dietary Modification Trial.	Lesley Tinker	DM breast C. (796,0) ovarian C. (70,0) 4DFRs
AS402	AS402 - Biomarkers and risk of ALS	Alberto Ascherio	OS, CT ALS as underlying cause of death (121) Controls (242)
AS403	Systemic and breast-cancer specific autoimmunity in the WHI	Christine Parks	General population 100 Systemic lupus cases 368 breast cancer cases
AS407	A feasibility study to assess the accuracy of self-reported glaucoma outcomes and participant interest in participating in ancillary hlaucoma studies	Thasarat Vajaranant	CAREDS and WHISE participants in MWRC Self-reported glaucoma (200)
AS411	Novel predictors of excess mortality in women with rheumatoid arthritis	Rachel Mackey	General population Controls (162) 162 BAA20 with anti-CCP+ RA participants who died during follow-up
AS413	Feasibility of sleep apnea assessment in WHI participants: Prelude to an ancillary study of sleep, cardiovascular disease and cognitive impairment	Katie Stone	WHIMS participants (56)
AS414	Social networks and health among women in the WHI: A new area of inquiry?	Crystal Wiley Cené	SE RC participants Non-Hispanic white (50) African American (50) Hispanic (50)
AS415	Assessing DNA methylation relationships in blood and tumor tissue	Kathy Malone	General population breast C. - invasive (60,0) 60 participants from W47 BTTP with tumor specimen available
AS416	Biomarkers of human age and longevity	Robert Reis	General population Controls (300) 100 women with plasma from baseline and Long Life Study; 100 short-lived and 100 long-lived women
AS417	Dietary metabolite profiling of nutrition and physical assessment	Dan Raftery	General population Controls (50) 50 NPAAS-FS
AS422	Measuring cardiovascular biomarkers in WHI Native Americans	Charles Kooperberg	General population Controls (594) PAGE Native Americans - 594 (same as pull M6-350)
AS423	Validating Multiple Stable Isotope Measures of Diet Within the NPAAS Feeding Study (AS272)	Diane M. O’Brien	NPAAS-FS (AS272) participants (153)
AS425	A Pilot Study of Urinary Bisphenol-A in the Womens Health Initiative	Juhua Luo	General population
AS427	(Pilot study II) Trial of a cocoa supplement and multivitamin for CVD and cancer prevention among WHI participants	JoAnn Manson	General population
AS438	Novel Hemorrhagic Stroke Risk factors in WHI: Pilot Study
AS439	Nutrition and physical activity interest survey	Marian Neuhouser
AS455	Helicobacter pylori protein-specific antibodies and colorectal cancer risk	Meira Epplein	OS Colorectal cancer (807) Controls (807)
AS458	Phthalate Metabolite and Breast Cancer Risk in the Women’s Health Initiative	Katherine Reeves	BMD Invasive breast cancer diagnosed after AV3 (500) Controls (1000)
AS461	Epigenetics, dietary intake and ovarian cancer risk	Jeanine Genkinger	OS, CT Epithelial ovarian cancer (610) Controls (610)
AS464	Classification of participants in the WHI by rural-urban residence	Michael Simon	General population
AS471	Macular pigment in aging and age-related eye disease	Julie Mares Kristin Meyers	OS CAREDS (AS105) survivors (1254)
AS476	APOL1, sickle cell trait and chronic kidney disease in African Americans	Nora Franceschini	CT, OS, BMD
AS482	Serologic inflammatory markers and esophageal adenocarcinoma risk	Michael Cook	CT, OS Esophageal adenocarcinoma (51) Controls (51)
AS498	Nutrition and Physical Activity Assessment Study (competitive renewal)	Marian Neuhouser Johanna Lampe	CT, OS BMD participants with history of invasive breast, ovarian, endometrial, colorectal cancer (708) Controls (708) NPAAS (AS218) participants (450)
AS504	A pilot study of a novel qPCR-based measure of relative Telomere Length in the Women’s Health Initiative	Tim Assimes	CT, OS White BA25 (non-cases) with available buffy coat and baseline 5' DNA (70) White AS254 participants with available buffy coat and baseline 5' DNA (25) Black BA25/AS254 overlap participants with available basline 5' DNA (25)
AS505	Validation of colorectal cancer early detection markers	Paul Lampe	OS Colorectal cancer (288) Controls (576)
AS508	Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing	Allison Kurian	CT,OS Invasive breast cancer (2,500) Controls (2,500)
AS509	Biomarkers of lung cancer risk	Mattias Johansson	CT control arms, OS 1321 participants with 1335 bio-specimens (445 lung cancer cases/ 890 sub-cohort members)
AS516	APOL1, sickle cell trait and chronic kidney disease in aging women	Nora Franceschini	CT, OS African Americans not in PAGE 2 (AS349) (6304)
AS518	AS518 - A pilot RNA-seq study among Long Life Study participants of the WHI	Tim Assimes	Long Life Study (LLS) African American LLS participants with no history of CVD, no incident CHD, and who have global DNA methylation (BAA23) and telemore (BAA25) (100)
AS523	Feasibility study to evaluate haptoglobin phenotype and risk of coronary heart disease and stroke among diabetic women	Richard Donahue	OS (400) 100 diabetic w/ Hx of CHD/revascularization 100 diabetic w/ Hx of stroke 100 diabetic w/ no Hx of stroke or CHD 100 non-diabetic w/ no Hx of stroke or CHD
AS525	Assessing sodium and potassium in 24-h and spot urines: feasibility of calibrating self-reported diet for use in WHI CVD association studies	Lesley Tinker	NPAAS-FS (AS272) NPAAS-FS participants (153)
AS534	Longitudinal study of DNA methylation as a mediator between age and cardiovascular risk	Karen Conneely	Long Life Study (LLS) AS315 participants with prior methylation analysis at two time points, and LLS DNA available for methylation analysis (43)
AS536	Targeted serum metabolites profiling in early detection of pancreatic cancer	Li Jiao	OS, non-active DM arm Pancreatic cancer (48) Controls (48)
AS537	A novel endogenous SERM and cholesterol metabolite, 27-hydroxcholesterol, and fracture risk in postmenopausal women	Jennifer S. Lee	BAA07/W9 participants Hip fracture (242) Vertebral fracture (200) Controls (430)
AS538	Genomic Analysis of Breast Cancer Genes in the WHI: Creation of a Public Genomics Resource	Mary-Claire King	CT, OS Participants in follow-up and cancer-free until at least age 65 (30,000)
AS543	Exploring WBC BRCA1 methylation as a risk factor for incidental cases of high grade serous ovarian cancer and triple-negative breast cancer in WHI	Per E. Lonning	CT, OS Triple-negative breast cancer (668) Ovarian cancer (549) Controls (3928)
AS545	Prospective identification of pre-leukemic clones in the peripheral blood of women with acute myeloid leukemia prior to the onset of overt disease	Pinkal Desai	CT, OS AML (213) Therapy related AML (13) Controls (210)
AS560	Serum and urine metabolite profiles of diet measured by weighed food	Steven C. Moore Mary C. Playdon	NPAAS Feeding Study (AS272) Participants (153)
AS562	Sex steroid hormones in women and development of primary liver cancer	Katherine McGlynn	CT Liver cancer (26) Controls (78) OS Liver cancer (90) Controls (165)
AS564	Trans-Omics for Precision Medicine (TOPMed)	Charles Kooperberg	CT, OS Ischemic stroke (4000) VTE (1100) Hemorrhagic stroke (900) Controls (5100)
AS575	Arsenic metabolic efficiency and risk of diabetes and cardiovascular disease	Krystal Pollitt	CT, OS AS466 participants Diabetes (400) Stroke (400) CHD (400) Controls (800) Additional cases Stroke (160) CHD (320)
AS584	Epigenetic Age as a Marker of Reproductive Age and Modifier of Invasive Breast Cancer Risk among Postmenopausal Women	Alexandra Binder	BA23, AS311, AS315 Existing genome-wide DNA methylation data (5,406)
AS590	Asprosin, body weight, and risk of type 2 diabetes in U.S. men and women	Simin Liu	CT, OS 8362 participants (4,181 incident diabetes; 4,181 controls) for whom imputed GWAS data (SHARe / GARNET) or exome sequencing data or whole genome sequencing data are available.
AS591	Genomic Characterization of Lung Cancer in Female Never-Smokers	Alice Berger	LILAC lung cancer cases with adenocarcinoma histology (150) never-smokers (130) "heavy" smokers (20)
AS593	The Women’s Health Initiative (WHI) Industry and Occupation Coding	Yvonne Michael	OS Participants responding to occupational history questionnaire at baseline (91,627)
AS603	PREcision Disease preventIon via somatiC muTagenesis enumeratION (PREDICTION)	Jason Bielas	OS Cancer cases (675) Controls (450)
AS608	Metabolomics, bacterial translocation and risk of liver cancer	Katherine McGlynn	CT, OS Participants from AS296 (240) Liver cancer (120) Controls (120) New cases (137) and controls (137)
AS611	Effect of clonal hematopoiesis of indeterminate potential and calcium and Vitamin D supplementation on risk of hematological malignancies	Pinkal Desai	CT, OS Aim 1 DLBCL (200) CLL (200) Controls (400) Aim 2 Hematologic malignancies (333) Controls (333)
AS615	Investigating the Biology of Cognitive Resilience in WHIMS “APOE 4 Escapees”	Susan Resnick	WHIMS participants Cognitively impaired (900) Controls (725)
AS620	PanScan Genome-Wide Association Study for Pancreatic Cancer	Laufey Amundadottir/ Rachael Stolzenberg-Solomon	CT, OS Pancreatic cancer cases (600) Controls (600)
AS622	Biomarkers of oxidative stress, inflammation, and cardiac damage as markers of radiation-induced cardiovascular outcomes in breast cancer	Alexi Vasbinder	LILAC Cardiotoxicity among breast cancer (~55) Controls (165)
AS624	Sleep, Metabolomics and Cardiovascular Health in Older Men and Women	Katie Stone	LLS-OPACH Aim 1 All ppts with accelerometry data. Aim 2 CVD cases (375) Controls (750)
AS628	Clonal Hematopoiesis of Indeterminate Potential (CHIP)	Alex Reiner/ Eric Whitsel	LLS participants (7800)
AS629	Rest-activity rhythms, dementia and Alzheimer's disease in older men and women: the role of metabolism and inflammation	Qian Xiao	LLS-OPACH, WHIMS 175 cognitive decline from LLS-OPACH + 425 controls (controls may be shared with AS624); Pilot: 75 cases with Alzheimer’s disease and related dementias [ADRD] and 75 controls who participated in WHIMS and LLS-OPACH
AS630	Autoantibodies for Small Cell Lung Cancer Early Detection	Paul Lampe	CT, OS Small-cell lung cancer (80) Controls (160)
AS637	Investigating the Biology of Cognitive Resilience in WHIMS “APOE ε4 Escapees” using Blood Exosomes	Dimitrios Kapogiannis/ Susan Resnick	WHIMS
AS649	Role of FSH in postmenopausal obesity and breast cancer	Jennifer Bea	BMD/AS15, AS98, AS382 From BMD/HT: 1,400 ( 95 cases + 1,305 controls) From BMD/non-HT: 1,210 ( 605 cases + 605 controls) From OsteoPerio Study: 685 (85 cases + 600 controls)
AS654	Blood Metabolomic Profile of Glioma Risk: A Collaborative Multi-Cohort Project	Demetrius Albanes	CT, OS Malignant glioma (250) Controls (250)
AS659	Women’s Health Initiative Study of Clonal Hematopoiesis of Indeterminate Potential and the Risk of Cognitive Decline and Impairment in Older Women	Kathleen Hayden	WHIMS and AS628 participants (4,500)
AS666	A Multi-omics Resource for Sickle Cell Trait in African Americans from the Women’s Health Initiative	Alex Reiner/ Charles Kooperberg	CT, OS 3,000 African Americans: Aim 1 (baseline samples requested): 2,000 (1,000 African American sickle cell trait [SCT] cases + 1,000 African Americans without SCT) Aim 2 (baseline + LLS samples requested): 1,000 LLS African Americans without multi-omics through TOPMed (AS576) Aim 3 (baseline samples requested, participants overlap with aims 1 and 2): 800 LLS African Americans without WGS through TOPMed or CCDG (AS564)
AS673	DNA methylation as a novel epigenetic biomarker that regulates metabolic and inflammatory cytokines in the development of obesity attributable cancers	Su Yon Jung	CT, OS Breast cancer (500) Controls (500)
AS678	NSAID use and tumor inflammatory biomarkers in relation to ovarian cancer risk and survival	Britton Trabert et al.	LILAC Invasive epithelial ovarian cancer (201)
AS687	Determinants of the racial/ethnic disparity in MGUS risk: An epidemiologic study in 4 cohorts	Pinkal Desai/ Wendy Cozen	CT,OS MGUS (877) Multiple myeloma (729) Controls (877)
AS689	Helicobacter Infection and Liver Cancer Risk among African Americans and Whites in the United States	Xuehong Zhang	CT, OS Liver cancer (325) Controls (750)
AS690	Epigenetic Aging Biomarkers of MCI, ADRD, and Brain Aging in the Women’s Health Initiative Memory Study	Aladdin Shadyab	WHIMS, LLS Mild cognitive impairment (1,336) Controls (7,504)
AS692	Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer	Ulrike Peters/ Amanda Phipps/ Shuji Ogino	LILAC ~450 CRC cases (All available cases with tumor tissue); only data is being requested for matched controls (1:4 ratio)
AS697	Air pollution adductomics and liver cancer risk	Trang VoPham	AS296 participants Hepatocellular carcinoma (18) Controls (72)
AS703	Association of sex steroid hormones and biliary tract cancers in men and women	Jill Koshiol	CT, OS Aim 1 Gallbladder cancer (41) Controls (82) Aim 2 Extrahepatic bile duct cancer (16) Controls (32)
AS714	Pilot study of sensitive and specific clinical biomarkers of B vitamin deficiency and relationship to AMD	Julie Mares Paul Jacques	OS, CAREDS Study Age-related macular degeneration (AMD, 100) Controls (100)
AS716	Feasibility of RNA sequencing using archival tumor specimens collected in WHI LILAC	Aditi Hazra	LILAC 8-12 breast tumor blocks and unstained slides
BA1	Ancestry association analyses of WHI traits	Michael Seldin	General population fracture - hip (950,950) Controls (22852) Hip fractures in Whites; Controls = 950 hip fx controls, 400 low/400 high BMD in Blacks; all Blacks 14,618; all Hispanics 6,484
BA2	High-dimensional genotype in relation to breast cancer and WHI clinical trial interventions	Ross Prentice	OS breast C. (2242,0) Controls (2242)
BA3	Genome-wide association study to identify genetic components of hip fracture	Rebecca Jackson	General population fracture - hip (2250,0) Controls (2250) Stage I: 750 non-minority os cases/controls, Stage II: 1108 (350 OS+758 CT) cases/controls
BA4	Proteomics and the health effects of postmenopausal hormone therapy	Ross Prentice	OS breast C. (800,800) stroke (800,800) chd (800,800) Controls (2400) Exclude 490 breast cancer cases from BA05-Li
BA5	Identification and validation of circulating biomarkers for the early detection of breast cancer in pre-clinical specimens	Rongling Li	OS breast C. (930,0) Controls (930) cases 6-19 months after baseline or Y3 blood draw
BA6	Interaction effects of genes in the inflammatory pathway and dietary, supplement, and medication	Jianfeng Xu	OS colorectal C. (600,0) C. of lung (564,0) breast C. (719,0) Controls (2120) 500 each in Whites, up to 500 in Blacks
BA7	Endogenous estradiol and the effects of estrogen therapy on major outcomes of WHI	Steve Cummings	HT vte (422,0) stroke (534,0) fracture - not hip or spine (830,0) chd (753,0) fracture - spine only (204,0) Controls (873) Prob Dement/Mild Cog Impair (310); Cohort (563 = original 351+212 added June 2010)
BA8	Predictive value of nutrient biomarkers for CHD death	Alice Lichtenstein	OS chd (1224,0) Controls (1224) add 2% cases/controls, include all CHD deaths
BA9	Biochemical antecedents of fracture in minority women	Jane Cauley	OS fracture (general) (1132,0) Controls (1132) Exclude spine fx
BA10	Adipokines and risk of obesity-related disease	Gloria Ho	OS breast C. (900,900) stroke (970,972) colorectal C. (500,500) endometrial C. (300,300) Controls (1870) Same as AS126-Stroke and AS129-Ins-Glu
BA11	Physical activity, obesity, inflammation and CHD in a multi-ethnic cohort of women	I-Minn Lee	OS chd (601,0) Controls (1332) Baseline+Y3:all Black, Hispanic, Asian, White up to 600 in cases; 300 of each ethnicity for controls
BA12	Hormone therapy, estrogen metabolism and risk of breast cancer or hip fracture in the WHI hormone trial	Lew Kuller	HT fracture - hip (370,0) breast C. (900,0) Controls (1800) Breast Cancer controls from W10-Breast Cancer core study
BA13	Markers of B-cell stimulation as potential predictors of Non-Hodgkins lymphoma	Anneclaire DeRoos	OS lymphoma, non hodgkins (487,0) Controls (487)
BA14	Inflammation and thrombosis gene pathways and cardiovascular disease	Alexander Reiner	General population chd (3594,3594) stroke (2887,2887) vte (632,632) Controls (4361) HT with OS to fill out controls
BA15	Discovery and confirmation of cancer specific serum protein markers for ovarian cancer early detection	Martin McIntosh	OS ovarian C. (225,0) Controls (225) Dx within 36 mo of blood draw
BA16	Identifying biomarkers for pancreatic cancer	Sunil Hingorani	OS pancreatic C. (280,0) Controls (280)
BA17	Proteomics based discovery of blood based biomarkers and risk factors for lung cancer among women smokers and never smokers	Sam Hanash	OS C. of lung (320,0) Controls (320) 30 pools of 10; 30 pools of 16
BA18	Followup studies of genetically determined risk factors	Rebecca Jackson	General population fracture - hip (400,0) Controls (7900) 2000 highest BMD + 2000 lowest BMD among non-Hispanic, non-Black for SNPs, subset of 400 for biomarkers; Mod for Stage #: 1500; Mod for Exome chip: 2000 (in addtion to 4000 previously included)
BA19	Omega-3 fatty acid biomarkers and cognitive decline in WHIMS	William S. Harris	HT Controls (7371) WHIMs ppts (1382 MRI, 1215 WHISCA, 4774 other)
BA20	Evaluation of specific markers of rheumatoid arthritis, Inflammation, thrombogenesis and risk of cardiovascular disease and total mortality	Larry W. Moreland	General population Controls (9988) 9,988 self-reported RA
BA21	Understanding the role of sex hormones in colorectal cancer	Marc Gunter	CT colorectal C. (400,0) Controls (800) excluding those in active HT arms
BA22	Predictive modeling for CVD in a multiethnic cohort in women	Nancy Cook	OS death - other cause (289,0) chd (933,0) stroke (812,0) Controls (2000) includes all CHD and strokes from 3 minority groups
BA23	Integrative genomics for risk of CHD and related phenotypes in the WHI	Phil Tsao	General population chd (1070,0) Controls (1070) Whites in HT GWAS (W63/M13 & W58) & Blacks/Hispanics in SHARe & W54
BA24	Metabolomics of CHD in the WHI	Kathryn Rexrode	General population chd (2210,0) Controls (2210)
BA25	Leukocyte telomere dynamics, cardiovascular aging and survival in the WHI Long Life Study in the WHI Long Life Study	Alexander Reiner	General population
M1	Diet and lifestyle factors reducing risk for age-related eye disease (AS105 extension)	Julie Mares	OS
M3	NCI Cancer Genetic Markers of Susceptibility (CGEMS) Initiative: Replication Phase	Stephen Chanock	OS breast C. (2956,0) Controls (2956) Caucasians only.
M4	Whole genome scan for pancreatic cancer risk in the pancreatic cancer cohort consortium (PANSCAN)	Rachael Stolzenberg-Solomon	General population pancreatic C. (283,0) Controls (283)
M5	SHARe (SNP Health Association Resource) GWAS		General population Controls (12007) Blacks, Hispanics who signed Supplemental Consent
M6	Population Architecture using Genomics and Epidemiology (PAGE)	Charles Kooperberg	General population breast C. - invasive (1961,0) ovarian C. (703,0) stroke (3455,0) lymphoma, non hodgkins (843,0) endometrial C. (1103,0) melanoma - skin (1102,0) C. of lung (1751,0) chd (4274,0) type 2 diabetes (4000,0) colorectal C. (1436,0) Controls (16000) ~20,000 ppts (cases & controls) every year for 4 years (new set of outcomes each year)
M8	NCI GWAS in bladder cancer	Stephen Chanock	General population C. of bladder (420,0) Controls (420) All non-Hispanic Caucasians; 28 non-dbGaP cases only for Taqman
M9	NCI GWAS in renal cell carcinoma (RCC): expansion of a primary scan	Mark Purdue	General population C. of kidney (299,0) Controls (298) Non-Hispanic caucasians; 20 dbGaP ineligible ppts for Taqman only.
M11	NCI - Upper GI cancer GWAS and telomere length evaluation (includes M10)	Phil Taylor	General population C. of stomach (145,0) C. of esophagus (28,38) Controls (346) Esophagus cancer have only GWAS
M12	Use of urinary sugars biomarker to assess measurement error structure of self-reported intake in NPAAS	Victor Kipnis	DM Controls (450) 450 NPAAS ppts
M13	Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials	Alexander Reiner	HT/OS stroke (351,351) chd (520,520) vte (313,313) type 2 diabetes (1080,0) Controls (2805) Controls #s include 174 case/control pairs with multiple outcomes, 200 SHARe ppts
M16	International Stroke Genetics Consortium	Sylvia Wassertheil-Smoller	OS stroke (844,0) dbGaP eligible cases from AS126
M18	Breast cancer post GWAS	David Hunter	General population breast C. (5766,0) Controls (5437) Caucasians from W21, BA2, and M6
M24	WHI Sequencing Project (WHISP)	Rebecca Jackson	General population type 2 diabetes (165,0) mi (161,161) stroke (770,340) Controls (1865) Phase I: BMI/T2D, early MI. Phase II: Stroke, Hypertension, Deeply Phenotyped Reference Group (DPR); Phase III: extra BMI and Stroke; Replication: 8950 samples (stroke+controls 3000; EOMI+Controls 5000; BP hi/lo 950 )
M25	GWAS of chronic periodontitis	Jean Wactawski-Wende	OS
M26	The colorectal cancer sequencing project (Phase II/III)/Whole Exome Sequencing for Colorectal Cancer (Phase I)	Ulrike Peters	General population colorectal C. (3000,0) Controls (2600) Caucasians only
W1	Core Analytes in a 6% Subsample
W2	OS-measurement precision study (OS-MPS)		OS Controls (800) B, 3 month
W3	Misc Core pulls		General population Place holder for QA pulls for labeling blind dups, cholesterol pulls to PPD for aliquoting QC
W4	National validation and quality control assurance of vitamin D absorption from CaD tablets for WHI		CaD Controls (448) Y3
W5	Correlates of endogenous sex hormone concentrations in DM trial		DM Controls (300) 150 DM Intervention + 150 DM controls at B and Y1
W6	HT CVD Biomarkers: study of CHD, Stroke and VTE - Phase I		HT stroke (272,272) chd (402,402) vte (223,223) Controls (877) B, Y1
W7	Genome-wide scan on breast cancer, CHD, and stroke		General population chd (2119,2219) stroke (2215,2013) breast C. (2145,2245) Controls (6479)
W8	Nutritional biomarkers study (NBS)		General population chd (2119,2219) stroke (2215,2013) breast C. (2145,2245) Controls (6479)
W9	Biological markers of the effect of HT on risk of fractures in the Women's Health Initiative clinical trial		HT fracture - hip (750,0) Controls (750) Cases=248 hip fractures + 502 non-spine fractures
W10	Biological markers of the effect of HT on risk of breast cancer in the Women's Health Initiative clinical trial		HT breast C. (755,0) Controls (755) 498 E+P and 260 E-Alone cases through Sept 2005; B+Y1
W11	CVD biomarkers - Phase II: strokes after Feb. 2001		HT stroke (326,0) Controls (326) 108 new E+P cases up to July 2002, 174 E alone cases up to March 2004; B+Y1
W14	CVD biomarkers - Phase I: additional asays		HT chd (390,402) stroke (270,272) vte (220,223) Controls (880) B, Y1
W15	Vitamin D levels in CaD participants with colorectal cancer or fractures		CaD fracture - elbow, lower humerous (853,0) fracture - hip (360,0) colorectal C. (334,0) fracture - spine only (283,0) Controls (1830) Y1; B only if Y1 not available
W18	HT Hormone Pretest		HT Controls (240) 120 active + 120 placebo; B, Y1
W19	WHI HT Proteomic Pilot Study		HT Controls (200) 100 active, 100 control; B, AV1
W20	WHI-EDRN pilot study for the identification of circulating biomarkers for colon cancer in pre-clinical specimens		OS colorectal C. (100,0) Controls (120) Colon cancer cases 6-18 mo after Year 3
W21	NCI Cancer Genetic Markers of Susceptibility (See study ref # M3)		OS breast C. (,0) Caucasians only.
W22	Vitamin D levels in 6% blood subsample of CaD		CaD Controls (600) CaD at AV1 and AV3, about 200 AA, 100 Hispanics, and 300 Caucasians
W24	Vitamin D and breast cancer in CaD trial		CaD breast C. (1081,0) Controls (1081) Use controls from W15 when possible
W25	WHI coronary artery calcification study in E-alone (WHI-CACS)	JoAnn Manson	HT 1150 E-Alone ppts aged 50-59
W27	Nutrition and physical activity assessment study (AS218) lab work		OS 450 ppts
W29	NCI Pancreatic Cancer Cohort Consortium (See study ref #M4)		General population pancreatic C. (,0)
W30	Dietary assessment study		DM 160 ppts for 4DFR analyses, repeat 24 hr recalls, and repeat FFQs
W31	4DFR on DM ovarian cancers		DM ovarian C. (160,0) For DM Other Cancer paper
W33	4DFR and DM breast cancer		DM breast C. (1800,0) For DM Breast Cancer paper
W34	Extension of WHI stroke genome-wide association study (W-7)		General population stroke (2096,0) Controls (2096)
W39	27-hydroxycholesterol in CVD biomarkers (W-6)		HT chd (359,0) Controls (820) CHD cases from W6-HT CVD Biomarkers
W40	Validation of E-alone proteins in W19-HT proteomics		HT Controls (100) 100 E-Alone ppts in active treatment arm
W43	Gene sequencing of selected genes in breast cancer and stroke SNP studies (W7 and W34)		HT E+P breast C. (60,0) Controls (60) 60 active treatment. 60 placebo
W44	Biological validation of E+P effects on the serum proteome and comparison of E+P and E-Alone effects (see W19 and W40)		HT Controls (50) 50 E+P ppts at baseline,AV1
W45	Proteomic Colon Cancer Study	Sam Hanash	OS colon C. (100,0) Controls (100)
W47	Breast Tissue Pilot Study	Garnet Anderson	504 DM ppts w/ invasive BC diagnosis
W54	CVD Biomarkers for 2010-2015 (SHARe cohort only)		General population Controls (12008) SHARe ppts (12,008)
W57	Proposal to Extend CVD Biomarker Study using HT Proteomics Study Findings on B2M and IGFBP2,4		General population stroke (341,341) chd (354,354) Controls (695)
W58	CVD, diabetes, and renal biomarkers in the EA HT Cohort		HT Controls (10254) AS39-WHIMS (6061) + M13-GARNET (3015) + subset of HT EA aged 65 and over (279) and under 65 (899)
W59	Collaborative telomere studies pilot study	Jacques Rossouw	HT Controls (60)
W63	GWAS on WHIMS and subsample of HT EA women		HT Controls (5907) Non-GARNET WHIMS (4661) + HT EA ppts aged 65+ (300) and under 65 (946)
W64	Long Life Study	Andrea LaCroix	General population 8,000 MRC ppts with GWAS and Baseline Biomarkers
W66	Long Life Study-Phase III Biomarkers and GWAS		General population Controls (1500) Ppts are the 1500 Phase III women in the Long Life Study. Unlike women in LLS Phases I &2, these women were not included in W54 or W58 and also not included in M5, M13, or W64.

WHI Study Pages // <![CDATA[ _spBodyOnLoadFunctionNames.push("setupPageDescriptionCallout"); // ]]>

WHI Study Pages

Note: This landing page is still being maintained, but may eventually be phased out. To search for and learn about our Ancillary Studies, please consider visiting the "Studies" page on the new WHI website.

WHI Study Pages